ITRA20130015A1 - COMPOUND AIMED AT IMPROVING BREATHING - Google Patents

COMPOUND AIMED AT IMPROVING BREATHING

Info

Publication number
ITRA20130015A1
ITRA20130015A1 IT000015A ITRA20130015A ITRA20130015A1 IT RA20130015 A1 ITRA20130015 A1 IT RA20130015A1 IT 000015 A IT000015 A IT 000015A IT RA20130015 A ITRA20130015 A IT RA20130015A IT RA20130015 A1 ITRA20130015 A1 IT RA20130015A1
Authority
IT
Italy
Prior art keywords
balsamic
compound according
blend
oil
compound
Prior art date
Application number
IT000015A
Other languages
Italian (it)
Inventor
Claudio Trere
Original Assignee
No & C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by No & C filed Critical No & C
Priority to IT000015A priority Critical patent/ITRA20130015A1/en
Publication of ITRA20130015A1 publication Critical patent/ITRA20130015A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/14Alkali metal chlorides; Alkaline earth metal chlorides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13Coniferophyta (gymnosperms)
    • A61K36/14Cupressaceae (Cypress family), e.g. juniper or cypress
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534Mentha (mint)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/61Myrtaceae (Myrtle family), e.g. teatree or eucalyptus

Description

"COMPOSTO FINALIZZATO AL MIGLIORAMENTO DELLA "COMPOUND AIMED AT THE IMPROVEMENT OF

RESPIRAZIONE. " BREATHING. "

DESCRIZIONE DESCRIPTION

La presente invenzione à ̈ relativa ad un composto finalizzato al miglioramento della respirazione. The present invention relates to a compound aimed at improving respiration.

Il composto in oggetto à ̈, in particolare, costituito da cristalli di Sodio cloruro (NaCl) puro, di tipo alimentare, di origine minerale o anche marina, addizionati con miscela balsamica di oli essenziali. Le deficienze respiratorie che si riscontrano al giorno d'oggi, peraltro in notevole aumento, sono causate in prevalenza da tabagismo, inquinamento dell'aria, allergie acquisite e congenite, malattie professionali. La scienza medica dà un contributo fondamentale per la diagnosi e la cura di tali patologie nelle persone colpite. The compound in question is, in particular, made up of pure sodium chloride (NaCl) crystals, of food type, of mineral or even marine origin, added with a balsamic blend of essential oils. The respiratory deficiencies that are found nowadays, however on a considerable increase, are mainly caused by smoking, air pollution, acquired and congenital allergies, occupational diseases. Medical science makes a fundamental contribution to the diagnosis and treatment of these diseases in those affected.

In affiancamento alle cure indispensabili sono stati creati, presso cliniche, terme e centri benessere, dei luoghi specifici definiti "grotte del sale", per la respirazione dell'aria salina da tempo riconosciuta benefica. Alongside the indispensable treatments, specific places called "salt caves" have been created in clinics, spas and wellness centers, for breathing in the saline air which has long been recognized as beneficial.

All'affermarsi della respirazione salina quale coadiuvante terapico ha molto contribuito l'sistenza di grandi centri assistiti sorti da molto tempo nelle grotte sotterranee scavate nel salgemma per l'estrazione dello stesso. The existence of large assisted centers which have arisen for a long time in the underground caves dug into the rock salt for its extraction has greatly contributed to the affirmation of saline respiration as a therapeutic adjuvant.

Questi centri si trovano in Germania, in Polonia e in altri paesi, e lì il paziente sosta durante il giorno per determinati periodi consigliati. These centers are located in Germany, Poland and other countries, and the patient stays there during the day for certain recommended periods.

Quanto descritto à ̈, in sostanza, lo stato attuale della tecnica della coadiuvazione naturale a base salina atta a migliorare la respirazione. What has been described is, in essence, the current state of the technique of natural salt-based aid to improve breathing.

Premesso questo, l'idea inventiva in oggetto à ̈ maturata per agevolare 1'utilizzatore nella reperibilità di un prodotto facilmente disponibile a breve distanza, riducendo il tempo e i costi di uno spostamento forzato. Having said this, the inventive idea in question was developed to facilitate the user in the availability of a product easily available at a short distance, reducing the time and costs of a forced movement.

Il preparato, in funzione della sua formulazione, mostra efficacia per la sinergia benefica sviluppata durante l'inspirazione dell'aria salina con gli aromi derivanti dagli oli essenziali balsamici Menta piperita, Eucalipto, Ginepro (Miscela balsamica), o anche solo Menta piperita Eucalipto, sostanze queste indicate allo scopo e riconosciute dalla letteratura scientifica riferita alle piante medicinali. The preparation, according to its formulation, shows efficacy for the beneficial synergy developed during the inhalation of saline air with the aromas deriving from the balsamic essential oils Peppermint, Eucalyptus, Juniper (Balsamic blend), or even just Peppermint Eucalyptus, these substances indicated for the purpose and recognized by the scientific literature referring to medicinal plants.

In sintesi, i microgranuli salini inspirati con gli oli balsamici aromatici agiscono positivamente aumentando la funzionalità degli alveoli bronchiali, favorendo una capacità respiratoria maggiore con azione lievemente batteriostatica. In summary, the saline microgranules inspired with the aromatic balsamic oils act positively by increasing the functionality of the bronchial alveoli, favoring a greater respiratory capacity with a slightly bacteriostatic action.

Sono scientificamente riconosciute l'azione batteriostatica del sale e l'azione antiinfiammatoria degli oli essenziali sopracitati. Una riflessione non di secondaria importanza riguarda i componenti, i quali non sono molecole sintetiche ma naturali. The bacteriostatic action of salt and the anti-inflammatory action of the aforementioned essential oils are scientifically recognized. A reflection not of secondary importance concerns the components, which are not synthetic but natural molecules.

L'inspirazione può avvenire con un apposito strumento di dimensioni anche tascabili che, una volta caricato del sale , consente il passaggio dell'aria attraverso il prodotto con effetto dì trascinamento dell'aria salina balsamica. Inoltre il prodotto può anche essere utilizzato in soluzione acquosa vaporizzata. The inhalation can take place with a special instrument, even pocket-sized, which, once loaded with salt, allows the passage of air through the product with the effect of entrainment of the balsamic saline air. Furthermore, the product can also be used in a vaporized aqueous solution.

I componenti del prodotto finito sono i seguenti: 1) SODIO CLORURO puro Food Grade (NaCl), di origine minerale, definito anche salgemma o sale di roccia, o anche di orìgine marina, senza additivi o coadiuvanti all'origine, a cristalli traslucidi. Titolo 99% minimo - Granulometria: 10-15% > 3,5 mm, 75-80% da 1 a 3,5 mm, 7-10% < 1 mm. The components of the finished product are as follows: 1) SODIUM CHLORIDE pure Food Grade (NaCl), of mineral origin, also defined as rock salt or rock salt, or even sea salt, without additives or adjuvants at the origin, in crystals translucent. 99% minimum titre - Granulometry: 10-15%> 3.5 mm, 75-80% from 1 to 3.5 mm, 7-10% <1 mm.

La diversificazione granulometrica dei cristalli salini à ̈ essenziale per formare le vie preferenziali del passaggio dell'aria di respirazione, che trascina microgranuli volatili e aromi balsamici; The granulometric diversification of the salt crystals is essential to form the preferential ways for the passage of the breathing air, which carries volatile microgranules and balsamic aromas;

2) Miscela balsamica Food grade costituita da: Mentha piperita oil 40-70%, Eucalyptus globulus oil 20-50%, Juniperus communis oil 2-10% o anche Mentha piperita oil 40-70% Eucalyptus globulus oil 30- 2) Food grade balsamic blend consisting of: Mentha piperita oil 40-70%, Eucalyptus globulus oil 20-50%, Juniperus communis oil 2-10% or even Mentha piperita oil 40-70% Eucalyptus globulus oil 30-

La concentrazione della Miscela balsamica sul prodotto finito à ̈ compresa nell'intervallo tra 50 e 500 ppm, concentrazioni queste adeguate a conferire efficacia al prodotto finito. The concentration of the balsamic blend on the finished product is between 50 and 500 ppm, these concentrations are adequate to give efficacy to the finished product.

Tale Miscela balsamica e il prodotto finito non sono soggetti a contaminazione batterica, non contengono antiossidanti e conservanti, sono esenti da OGM, non contengono sostanze classificate CMR di categoria 1,2 o 3 (informazione basata sulla direttiva 2003/15/CE e 63/548/CE per le sostanze carcinogene, mutagene o tossiche) , non sono venuti a contatto in produzione con derivati di origine animale, non sono stati trattati con radiazioni ionizzanti, sono esenti da solventi residui, contaminanti, metalli pesanti, ftalati e glicoli. This balsamic blend and the finished product are not subject to bacterial contamination, do not contain antioxidants and preservatives, are free from GMOs, do not contain substances classified as CMR category 1,2 or 3 (information based on directive 2003/15 / EC and 63 / 548 / EC for carcinogenic, mutagenic or toxic substances), have not come into contact in production with derivatives of animal origin, have not been treated with ionizing radiation, are free from residual solvents, contaminants, heavy metals, phthalates and glycols.

Il procedimento di preparazione del composto in oggetto à ̈ il seguente. The preparation procedure of the compound in question is as follows.

In un particolare mescolatore in acciaio inox a rotazione decentrata si pone il sale da aromatizzare con la Miscela balsamica, la quale à ̈ aggiunta in tre parti, in tre momenti della miscelazione. The salt to be flavored with the balsamic blend is placed in a particular stainless steel mixer with decentralized rotation, which is added in three parts, in three stages of mixing.

Il prodotto finito à ̈ scaricato dal mescolatore e versato nella tramoggia di una inflaconatrice per la formazione, chiusura e relativa etichettatura dei flaconi. The finished product is discharged from the mixer and poured into the hopper of a bottle filling machine for the formation, closure and relative labeling of the bottles.

I flaconi confezionati sono finalizzati a ricostituire la carica di prodotto fresco, in sostituzione di quello esaurito, in una "pipa " di aspirazione con contenitore microforato alla base. The packaged bottles are designed to reconstitute the charge of fresh product, to replace the exhausted one, in a suction "pipe" with a micro-perforated container at the base.

Lo scuotimento del contenitore prima di ogni ciclo di aspirazione consente così di modificare la posizione dei cristalli di sale e quindi delle vie preferenziali di aspirazione, il rinnovo della superficie salina di contatto, la produzione di nuovi microcristalli. The shaking of the container before each aspiration cycle thus allows to modify the position of the salt crystals and therefore of the preferential aspiration routes, the renewal of the saline contact surface, the production of new microcrystals.

La "pipa" à ̈ dotata nella parte superiore di un piano anch'esso microforato per il passaggio dell'aria e il trattenimento del sale non conforme alla respirazione. La decadenza del prodotto à ̈ constatabile dall'esaurimento degli aromi, dopo 30/60 giorni dall'apertura del flacone, in funzione dell'intensità d'uso del prodotto stesso. The "pipe" is equipped in the upper part with a micro-perforated surface for the passage of air and the retention of salt that does not conform to breathing. The decadence of the product is ascertained from the exhaustion of the aromas, after 30/60 days from the opening of the bottle, depending on the intensity of use of the product itself.

La preparazione della Miscela balsamica à ̈ definita da una distinta base precostituita, che ne indica la quantità complessiva da impiegare e le relative percentuali e quantità dei componenti, in base alla quantità totale di prodotto determinata dalla commessa Per agevolare e consentire una razionale diffusione della Miscela balsamica aromatizzante nella massa salina si diluisce la stessa con l'aggiunta, in rapporto 1:10, di alcool etilico puro. The preparation of the balsamic blend is defined by a pre-established bill of materials, which indicates the overall quantity to be used and the relative percentages and quantities of the components, based on the total quantity of product determined by the order To facilitate and allow a rational diffusion of the Blend balsamic flavoring in the saline mass is diluted with the addition, in a ratio of 1:10, of pure ethyl alcohol.

La presenza di alcool etilico puro, anche se in minime quantità, favorisce la bio-stabilità della massa durante la lavorazione non aumentando il grado di umidità del prodotto finito; infatti l'alcool svanisce per evaporazione durante il processo di lavorazione e confezionamento senza lasciare residui. The presence of pure ethyl alcohol, even if in minimal quantities, favors the bio-stability of the mass during processing by not increasing the degree of humidity of the finished product; in fact the alcohol vanishes by evaporation during the manufacturing and packaging process without leaving residues.

Claims (8)

RIVENDICAZIONI 1. Composto comprendente del cloruro di sodio ed una miscela balsamica formata da oli essenziali vegetali aromatici e con una concentrazione compresa fra i 50 e 500 ppm. CLAIMS 1. Compound comprising sodium chloride and a balsamic blend formed by aromatic vegetable essential oils and with a concentration between 50 and 500 ppm. 2. Composto secondo la rivendicazione 1, caratterizzato dal fatto che la detta miscela balsamica comprende Menta piperita e Eucalipto. 2. Compound according to claim 1, characterized in that said balsamic mixture comprises Peppermint and Eucalyptus. 3. Composto secondo la rivendicazione 2, caratterizzato dal fatto che la detta miscela balsamica presenta la seguente formulazione: Mentha piperita oil 40-70% ed Eucalyptus globulus oil 30-60%. 3. Compound according to claim 2, characterized in that said balsamic blend has the following formulation: Mentha piperita oil 40-70% and Eucalyptus globulus oil 30-60%. 4. Composto secondo la rivendicazione 2 o 3, caratterizzato dal fatto che la detta miscela balsamica comprende inoltre Ginepro. 4. Compound according to claim 2 or 3, characterized in that said balsamic blend further comprises Juniper. 5. Composto secondo la rivendicazione 4, caratterizzato dal fatto che la detta miscela balsamica presenta la seguente formulazione: Mentha piperita oil 40-70%, Eucalyptus globulus oil 20-50%, Juniperus communis oil 2-10%. 5. Compound according to claim 4, characterized in that said balsamic blend has the following formulation: Mentha piperita oil 40-70%, Eucalyptus globulus oil 20-50%, Juniperus communis oil 2-10%. 6. Composto secondo una o più delle rivendicazioni precedenti da 1 a 5, caratterizzato dal fatto che il detto cloruro di sodio presenta la seguente granulometria: > 3,5 mm 10-15%, da 1 a 3,5 mm 75-80%, < 1 mm 7-10%. 6. Compound according to one or more of the preceding claims from 1 to 5, characterized in that said sodium chloride has the following particle size:> 3.5 mm 10-15%, from 1 to 3.5 mm 75-80% , <1 mm 7-10%. 7. Metodo di preparazione della miscela balsamica del composto secondo una o più delle rivendicazioni da 1 a 6, comprendente la diluizione della stessa detta miscela con l'aggiunta, in rapporto 1:10, di alcool etilico puro per favorire la bio-stabilità della massa durante la lavorazione senza aumentare il grado di 7. Method for preparing the balsamic mixture of the compound according to one or more of claims 1 to 6, comprising the dilution of said mixture with the addition, in a ratio of 1:10, of pure ethyl alcohol to favor the bio-stability of the mass during processing without increasing the degree of 8. Uso del composto secondo una o più delle rivendicazioni precedenti per il miglioramento ed il mantenimento benefico della respirazione.8. Use of the compound according to one or more of the preceding claims for the improvement and beneficial maintenance of respiration.
IT000015A 2013-06-12 2013-06-12 COMPOUND AIMED AT IMPROVING BREATHING ITRA20130015A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IT000015A ITRA20130015A1 (en) 2013-06-12 2013-06-12 COMPOUND AIMED AT IMPROVING BREATHING

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000015A ITRA20130015A1 (en) 2013-06-12 2013-06-12 COMPOUND AIMED AT IMPROVING BREATHING

Publications (1)

Publication Number Publication Date
ITRA20130015A1 true ITRA20130015A1 (en) 2014-12-13

Family

ID=49035811

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000015A ITRA20130015A1 (en) 2013-06-12 2013-06-12 COMPOUND AIMED AT IMPROVING BREATHING

Country Status (1)

Country Link
IT (1) ITRA20130015A1 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225394A1 (en) * 2002-06-04 2003-12-04 Peter Ahnblad Pharmaceutical composition and nasal rinsing device therefor
WO2005053638A2 (en) * 2003-11-29 2005-06-16 Passion For Life Healthcare Limited Composition and delivery system
US20060019987A1 (en) * 2004-07-23 2006-01-26 Fust Charles A Methods and compositions for inhibiting, destroying, and/or inactivating viruses
EP2528591A2 (en) * 2010-01-29 2012-12-05 Mahmut Bilgic Effervescent formulations comprising cefaclor
DE202013000748U1 (en) * 2013-01-24 2013-02-19 Merz Pharma Gmbh & Co. Kgaa Sprayable liquid preparation for especially nasal application with increased local residence time
EP2574333A1 (en) * 2011-09-27 2013-04-03 Friulchem SpA N-acetylcysteine effervescent tablet and its therapeutical applications

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225394A1 (en) * 2002-06-04 2003-12-04 Peter Ahnblad Pharmaceutical composition and nasal rinsing device therefor
WO2005053638A2 (en) * 2003-11-29 2005-06-16 Passion For Life Healthcare Limited Composition and delivery system
US20060019987A1 (en) * 2004-07-23 2006-01-26 Fust Charles A Methods and compositions for inhibiting, destroying, and/or inactivating viruses
EP2528591A2 (en) * 2010-01-29 2012-12-05 Mahmut Bilgic Effervescent formulations comprising cefaclor
EP2574333A1 (en) * 2011-09-27 2013-04-03 Friulchem SpA N-acetylcysteine effervescent tablet and its therapeutical applications
DE202013000748U1 (en) * 2013-01-24 2013-02-19 Merz Pharma Gmbh & Co. Kgaa Sprayable liquid preparation for especially nasal application with increased local residence time

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"SinoFresh Antiseptic Nasal Spray for Sinus Infection Symptoms", 29 May 2005 (2005-05-29), XP002714387, Retrieved from the Internet <URL:www.sinofresh.com/FAQ_SCIENCE.php> [retrieved on 20131008] *
MARK SANDERS: "Inhalation therapy: an historical review", PRIMARY CARE RESPIRATORY JOURNAL, vol. 16, no. 2, 1 April 2007 (2007-04-01), pages 71, XP055083133, ISSN: 1471-4418, DOI: 10.3132/pcrj.2007.00017 *

Similar Documents

Publication Publication Date Title
EA201390332A1 (en) DEUDIED PRIDOPIDINE ANALOGUES APPLICABLE AS DOPAMINER STABILIZERS
EA201100896A1 (en) COMPOSITION INTENDED FOR SUCKING NICOTINE FROM THE FATAL CAVITY WITH THE PURPOSE TO STOP SMOKING
PE20180522A1 (en) ORODISPERSABLE DOSING UNIT CONTAINING A STETROL COMPONENT
DOP2017000293A (en) ORODISPERSABLE DOSAGE UNIT CONTAINING A STETROL COMPONENT
BR112015027017A2 (en) inhalable pharmaceutical compositions and inhaler devices containing the same
JP6030687B2 (en) Pharmaceutical composition containing loxoprofen or a salt thereof Part 2
EA201401354A1 (en) NEW DOSED FORM AND PREPARATION CONTAINING ABEDTEROL
BR112015026053A8 (en) pharmaceutical composition, sealed container, metered-dose inhaler, use of a propellant component, and method for making a pharmaceutical composition
EA201691299A1 (en) APPLICATION OF LACHINIMODA TO SLOW DOWN THE PROGRESSION OF HANTINGTON&#39;S DISEASE
ITRA20130015A1 (en) COMPOUND AIMED AT IMPROVING BREATHING
BR112015014137A2 (en) fexofenadine solid unit and process for preparing it
BR112015020019A2 (en) tablet for the treatment of sore throat, hoarseness and associated dry cough and inflammatory diseases of the oral and pharyngeal cavity
MEP51608A (en) Pulverulent formulation for inhalation containing tiotropium
JP6087826B2 (en) Pharmaceutical composition containing loxoprofen or a salt thereof
Shamkuwar et al. Antidiarrhoeal activity of an ayurvedic formulation: Enterocin
MX348222B (en) Use of modafinil in the treatment of cocaine addicts.
CN107519470A (en) A kind of Chinese medicine composition for treating tinea pedis
Bugailiškis Šiaulių miesto bibliotekos ir jų raida
ZHANG et al. Effects of Daidzein on Bone Rebuiling of Alveolar Fossa after Tooth Extraction in Osteoporotic-model Rats.
PAN Establishment of incisor extraction wound rat models in aesthetic area and evaluation on effectiveness of modified minimally invasive tooth extraction surgery
IT202000025036A1 (en) ASSOCIATION OF PLANTS AND THEIR USE IN THE TREATMENT OF CHRONIC PERSISTENT OR NEUROPATHIC PAIN.
JP2014240370A (en) Pharmaceutical composition comprising loxoprofen
HRP20231108T1 (en) A pharmaceutical composition for enhancing iron levels in blood, comprising iron (iii) polymaltose and another active substance, suitable for iron absorption, selected from calcium folinate pentahydrate, vitamin c or a combination of both
ITMI20101426A1 (en) COMPOSITION CONTAINING CONDROITIN SULFATE
Mello et al. Anti-inflammatory, healing and antimicrobial properties of a 20% aqueous extract of aroeira-do-sertão (myracrodruon urundeuva fr. all.) applied to induced exposed fractures in rabbit jaws